Skip to main content

Table 1 Reported efficacy of rituximab in nonrandomised trials of systemic lupuserythematosus

From: B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumaband implications for study design

Study Rituximabregimen Organ-specificdisease Number ofpatients/follow-up(months) Method of assessment(mean disease activity score before/afterB-cell depletion)
Anolik and colleagues [64]; Looney and colleagues [26] Variable No (7 LN) 17/12 SLAM improved in patients achieving effective B-cell depletion (6.8/5.2)
Leandro and colleagues [15]b 2-dose No (17/19 LN) 19/6 BILAG (13.9/5)
Vigna-Perez and colleagues [65] 2-dose Yes, LN 22/3 Mexico-SLEDAI (10.8/6.8)
Cambridge and colleagues [21]b 2-dose No (12/15 LN) 15/6 BILAG
Tamimoto and colleagues [66] Variable No (4/8LN) 8 SLEDAI (17.6/7.3)
Tokunaga and colleagues [28] Variable Yes, NPSLE 10/7 to 45 Neurological parameters (GCS)
Tanaka and colleagues [67] 2-dose No (6LN) 14/7 BILAG (12.5/7.1)
Ng and colleagues [17]b 2-dose No (21 LN) 32/39 BILAG (13/5)
Reynolds and colleagues [45] Variable No 11/10 BILAG (median reduction of 7.5)
Li and colleagues [68], 2-dose Yes, LN 19/12 SLEDAI (9.2/2.5)
Lu and colleagues [69]b 2-dose No (33/45 LN) 45/39.6 BILAG (12/5)
Pepper and colleagues [56] 2-dose + MMF maintenance Yes, LN 20/12 Renal parameters improved in 14/18 at 12 months
Catapano and colleagues [19] 4-dose (15) or2-dose + CYC (16) No (11 LN) 31/30 BILAG (14.5/3.5 at 24 months)
Sfikakis and colleagues [70] 4-dose Yes, LN 10/12 Renal parameters
Gottenberg and colleagues [71] 4-dose No (4 LN) 13/8.3 SLEDAI (8/2)
Smith and colleagues [18] 4-dose, retreated with 2-dose No 11/24 BILAG (14/2)
Gunnarsson and colleagues [72] 4-dose Yes, LN 7/6 SLEDAI (15/3)
Galarza and colleagues [73] 4-dose No 43/12 SLEDAI (12.5/4.5)
Jonsdottir and colleagues [74] 4-dose No (10 LN) 16/27 SLEDAI (12.1/4.7)
Lindholm and colleagues [75] 4-dose No (17 LN) 29/22 Renal parameters
Sutter and colleagues [76] 4-dose No 12 SLEDAI (9/5)
Boletis and colleagues [77] 4-dose Yes, LN 10/38 Renal parameters
Melander and colleagues [78] 4-dose regimen (10 retreated) Yes, LN 20/22 12/20 improved
  1. BILAG, British Isles Lupus Assessment Group; CYC, cyclophosphamide; GCS, GlasgowComa Scale; MMF, mycophenolate mofetil; SLAM, systemic lupus activity measure; LN,lupus nephritis; NPSLE, neuropsychiatric systemic lupus erythematosus; SLEDAI,Systemic Lupus Erythematosus Disease Activity Index. aRandomisedcontrolled trial. bSame cohort in these studies.